Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7525148 | 1.00 | TP53 (0.36) | TP53SLC7A5 | |
| SCHEMBL7519833 | 0.77 | SLC7A5 (0.33) | TP53SLC7A5 | |
| SCHEMBL17234586 | 0.77 | SLC7A5 (0.33) | TP53SLC7A5 | |
| SCHEMBL7527981 | 0.77 | SLC7A5 (0.33) | TP53SLC7A5 | |
| SCHEMBL23744198 | 0.72 | TP53 (0.43) | TP53SLC7A5 | |
| SCHEMBL23566647 | 0.68 | — | — | |
| SCHEMBL1923463 | 0.68 | TP53 (0.42) | TP53SLC7A5 | |
| SCHEMBL1923464 | 0.68 | TP53 (0.42) | TP53SLC7A5 | |
| Lactic Acid SCHEMBL9940686 | 0.68 | — | — | |
| SCHEMBL2441109 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0793646-B1 | AMINOGUANIDINE CARBOXYLATES FOR THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS | UPJOHN CO (US) | 2001-09-05 | — | — | EP | claimed |
| US-5994577-A | Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus | PHARMACIA & UPJOHN COMPANY | 1999-11-30 | — | — | US | claimed |
| EP-0793646-A1 | AMINOGUANIDINE CARBOXYLATES FOR THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS | PHARMACIA & UPJOHN COMPANY (US) | 1997-09-10 | — | — | EP | claimed |
| WO-1996016031-A1 | AMINOGUANIDINE CARBOXYLATES FOR THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS | PHARMACIA & UPJOHN COMPANY (US) | 1996-05-30 | — | — | WO | claimed |
| US-20020082448-A1 | Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus | THE UPJOHN COMPANY | 2002-06-27 | — | — | US | disclosed |
| US-6329545-B1 | SYSTEMIC ADMINISTRATION OF .ALPHA.-((AMINOIMINOMETHYL)HYDRAZONO)-BENZENEPROPANOIC ACID OR ITS HYDROCHLORIDE SALT FOR THERAPY OF DIABETES | LARSEN SCOTT D (US) | 2001-12-11 | — | — | US | disclosed |
| EP-0793646-B1 | AMINOGUANIDINE CARBOXYLATES FOR THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS | UPJOHN CO (US) | 2001-09-05 | — | — | EP | disclosed |
| US-6166080-A | Aminoquanidine carboxylates for the treatment of obesity | PHARMACIA (US) | 2000-12-26 | — | — | US | disclosed |
| US-5994577-A | Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus | PHARMACIA & UPJOHN COMPANY | 1999-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082448-A1 | Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus | GPR119, IAPP, SLC5A2 | TP53 4838/4885SLC7A5 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.